LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 6 von insgesamt 6

Suchoptionen

  1. Artikel ; Online: We are on time.

    Higuera Lucas, Juan / Soriano Cuesta, Cruz / López Olivencia, Marina / Blandino Ortíz, Aaron

    The Lancet regional health. Western Pacific

    2022  Band 20, Seite(n) 100411

    Sprache Englisch
    Erscheinungsdatum 2022-02-27
    Erscheinungsland England
    Dokumenttyp Journal Article
    ISSN 2666-6065
    ISSN (online) 2666-6065
    DOI 10.1016/j.lanwpc.2022.100411
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  2. Artikel ; Online: The right care at the right place with the right specialist.

    Higuera Lucas, Juan / Soriano Cuesta, Cruz / De Pablo, Raúl / Blandino Ortíz, Aaron

    The Lancet regional health. Western Pacific

    2021  Band 14, Seite(n) 100247

    Sprache Englisch
    Erscheinungsdatum 2021-08-20
    Erscheinungsland England
    Dokumenttyp Journal Article
    ISSN 2666-6065
    ISSN (online) 2666-6065
    DOI 10.1016/j.lanwpc.2021.100247
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  3. Artikel ; Online: Multicentre study of cefiderocol for treatment of Gram-negative bacteria infections in critically ill patients.

    Balandín, Bárbara / Pintado, Vicente / Pérez-Pedrero, María José / Martínez-Sagasti, Fernando / Sancho-González, Milagros / Soriano-Cuesta, Cruz / Gesso, Cristina Martín-Dal / Chicot, Marta / de Luna, Rafael Ruiz / Asensio-Martín, María José / Catalan, Mercedes / Díaz-Díaz, Juan José / Carbonell, Nieves / Iranzo, Reyes / Royuela, Ana / Ballesteros, Daniel

    International journal of antimicrobial agents

    2024  Band 63, Heft 5, Seite(n) 107121

    Mesh-Begriff(e) Humans ; Critical Illness ; Anti-Bacterial Agents/therapeutic use ; Cefiderocol ; Cephalosporins/therapeutic use ; Gram-Negative Bacterial Infections/drug therapy ; Gram-Negative Bacterial Infections/microbiology ; Male ; Middle Aged ; Aged ; Female ; Gram-Negative Bacteria/drug effects ; Treatment Outcome
    Chemische Substanzen Anti-Bacterial Agents ; Cefiderocol (SZ34OMG6E8) ; Cephalosporins
    Sprache Englisch
    Erscheinungsdatum 2024-02-24
    Erscheinungsland Netherlands
    Dokumenttyp Letter ; Multicenter Study
    ZDB-ID 1093977-5
    ISSN 1872-7913 ; 0924-8579
    ISSN (online) 1872-7913
    ISSN 0924-8579
    DOI 10.1016/j.ijantimicag.2024.107121
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 3368: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 500: Hefte anzeigen

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  4. Artikel ; Online: Multicentre study of ceftazidime/avibactam for Gram-negative bacteria infections in critically ill patients.

    Balandín, Bárbara / Ballesteros, Daniel / Pintado, Vicente / Soriano-Cuesta, Cruz / Cid-Tovar, Irene / Sancho-González, Milagros / Pérez-Pedrero, María José / Chicot, Marta / Asensio-Martín, María José / Silva, José Alberto / de Luna, Rafael Ruiz / Gesso, Cristina Martín-Dal / Rodríguez-Serrano, Diego Aníbal / Martínez-Sagasti, Fernando / Royuela, Ana

    International journal of antimicrobial agents

    2022  Band 59, Heft 3, Seite(n) 106536

    Abstract: This study aimed to assess the efficacy of ceftazidime/avibactam (C/A) in the treatment of infections due to Gram-negative bacteria (GNB) in critically ill patients. A multicentre, retrospective, observational study was conducted in critically ill ... ...

    Abstract This study aimed to assess the efficacy of ceftazidime/avibactam (C/A) in the treatment of infections due to Gram-negative bacteria (GNB) in critically ill patients. A multicentre, retrospective, observational study was conducted in critically ill patients receiving C/A for GNB infections. We evaluated demographic data, localisation and severity of infection, clinical and microbiological outcomes, and mortality. A total of 68 patients received C/A for serious GNB infections. The main infections were respiratory (33.8%), intra-abdominal (22.1%) and urinary tract infections (10.3%); bacteraemia was found in 22 cases (32.4%). Most infections were complicated by septic shock (58.8%) or sepsis (36.8%) and most of them required life-supporting therapies. Enterobacterales (79.4%) and Pseudomonas aeruginosa (19.1%) were the most frequently isolated bacteria; 84.2% of isolates were carbapenem-resistant. Thirty-four patients (50.0%) received C/A in combination with other antimicrobials. Fifty patients (73.5%) presented a favourable clinical response. Microbiological eradication was documented in 25 cases (36.8%). No significant differences were found in clinical response between patients treated with monotherapy or combined therapy (79.4% vs. 67.6%; P = 0.27). Overall intensive care unit (ICU) mortality was 41.2%. Univariate analysis showed that 30-day all-cause mortality was significantly (P < 0.05) associated with bacteraemia, previous corticosteroid use and the need of life-supporting therapies. C/A appears to be an effective therapy for severe infections due to GNB, including carbapenem-resistant isolates, in critically ill patients. C/A combination therapy was not associated with a higher clinical response. Mortality correlated significantly with the presence of bacteraemia, previous corticosteroid use and the need for life-supporting therapies.
    Mesh-Begriff(e) Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Azabicyclo Compounds/therapeutic use ; Ceftazidime/therapeutic use ; Critical Illness ; Drug Combinations ; Drug Resistance, Multiple, Bacterial ; Gram-Negative Bacteria ; Gram-Negative Bacterial Infections/drug therapy ; Gram-Negative Bacterial Infections/microbiology ; Humans ; Microbial Sensitivity Tests ; Retrospective Studies
    Chemische Substanzen Anti-Bacterial Agents ; Azabicyclo Compounds ; Drug Combinations ; avibactam (7352665165) ; Ceftazidime (9M416Z9QNR)
    Sprache Englisch
    Erscheinungsdatum 2022-01-25
    Erscheinungsland Netherlands
    Dokumenttyp Journal Article ; Multicenter Study ; Observational Study
    ZDB-ID 1093977-5
    ISSN 1872-7913 ; 0924-8579
    ISSN (online) 1872-7913
    ISSN 0924-8579
    DOI 10.1016/j.ijantimicag.2022.106536
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 3368: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 500: Hefte anzeigen

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  5. Artikel: Multicentre study of ceftazidime/avibactam for Gram-negative bacteria infections in critically ill patients

    Balandín, Bárbara / Ballesteros, Daniel / Pintado, Vicente / Soriano-Cuesta, Cruz / Cid-Tovar, Irene / Sancho-González, Milagros / Pérez-Pedrero, María José / Chicot, Marta / Asensio-Martín, María José / Silva, José Alberto / de Luna, Rafael Ruiz / Gesso, Cristina Martín-Dal / Rodríguez-Serrano, Diego Aníbal / Martínez-Sagasti, Fernando / Royuela, Ana

    International journal of antimicrobial agents. 2022 Mar., v. 59, no. 3

    2022  

    Abstract: This study aimed to assess the efficacy of ceftazidime/avibactam (C/A) in the treatment of infections due to Gram-negative bacteria (GNB) in critically ill patients. A multicentre, retrospective, observational study was conducted in critically ill ... ...

    Abstract This study aimed to assess the efficacy of ceftazidime/avibactam (C/A) in the treatment of infections due to Gram-negative bacteria (GNB) in critically ill patients. A multicentre, retrospective, observational study was conducted in critically ill patients receiving C/A for GNB infections. We evaluated demographic data, localisation and severity of infection, clinical and microbiological outcomes, and mortality. A total of 68 patients received C/A for serious GNB infections. The main infections were respiratory (33.8%), intra-abdominal (22.1%) and urinary tract infections (10.3%); bacteraemia was found in 22 cases (32.4%). Most infections were complicated by septic shock (58.8%) or sepsis (36.8%) and most of them required life-supporting therapies. Enterobacterales (79.4%) and Pseudomonas aeruginosa (19.1%) were the most frequently isolated bacteria; 84.2% of isolates were carbapenem-resistant. Thirty-four patients (50.0%) received C/A in combination with other antimicrobials. Fifty patients (73.5%) presented a favourable clinical response. Microbiological eradication was documented in 25 cases (36.8%). No significant differences were found in clinical response between patients treated with monotherapy or combined therapy (79.4% vs. 67.6%; P = 0.27). Overall intensive care unit (ICU) mortality was 41.2%. Univariate analysis showed that 30-day all-cause mortality was significantly (P < 0.05) associated with bacteraemia, previous corticosteroid use and the need of life-supporting therapies. C/A appears to be an effective therapy for severe infections due to GNB, including carbapenem-resistant isolates, in critically ill patients. C/A combination therapy was not associated with a higher clinical response. Mortality correlated significantly with the presence of bacteraemia, previous corticosteroid use and the need for life-supporting therapies.
    Schlagwörter Pseudomonas aeruginosa ; adrenal cortex hormones ; bacteremia ; ceftazidime ; mortality ; observational studies ; septic shock ; therapeutics ; urinary tract
    Sprache Englisch
    Erscheinungsverlauf 2022-03
    Erscheinungsort Elsevier Ltd
    Dokumenttyp Artikel
    ZDB-ID 1093977-5
    ISSN 1872-7913 ; 0924-8579
    ISSN (online) 1872-7913
    ISSN 0924-8579
    DOI 10.1016/j.ijantimicag.2022.106536
    Datenquelle NAL Katalog (AGRICOLA)

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 3368: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 500: Hefte anzeigen

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  6. Artikel ; Online: Multicenter study of ceftolozane/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients.

    Balandin, Bárbara / Ballesteros, Daniel / Ruiz de Luna, Rafael / López-Vergara, Loreto / Pintado, Vicente / Sancho-González, Milagros / Soriano-Cuesta, Cruz / Pérez-Pedrero, Maria José / Asensio-Martín, Maria José / Fernández-Simón, Inamculada / Rodríguez-Serrano, Diego / Silva, Alberto / Chicot, Marta / Iranzo, Reyes / Martínez-Sagasti, Fernando / Royuela, Ana

    International journal of antimicrobial agents

    2021  Band 57, Heft 3, Seite(n) 106270

    Abstract: Background: This study aimed to assess the efficacy of ceftolozane-tazobactam (C/T) for treating infections due to Pseudomonas aeruginosa (P. aeruginosa) in critically ill patients.: Patients and methods: A multicenter, retrospective and ... ...

    Abstract Background: This study aimed to assess the efficacy of ceftolozane-tazobactam (C/T) for treating infections due to Pseudomonas aeruginosa (P. aeruginosa) in critically ill patients.
    Patients and methods: A multicenter, retrospective and observational study was conducted in critically ill patients receiving different C/T dosages and antibiotic combinations for P. aeruginosa infections. Demographic data, localisation and severity of infection, clinical and microbiological outcome, and mortality were evaluated.
    Results: Ninety-five patients received C/T for P. aeruginosa serious infections. The main infections were nosocomial pneumonia (56.2%), intra-abdominal infection (10.5%), tracheobronchitis (8.4%), and urinary tract infection (6.3%). Most infections were complicated with sepsis (49.5%) or septic shock (45.3%), and bacteraemia (10.5%). Forty-six episodes were treated with high-dose C/T (3 g every 8 hours) and 38 episodes were treated with standard dosage (1.5 g every 8 hours). Almost half (44.2%) of the patients were treated with C/T monotherapy, and the remaining group received combination therapy with other antibiotics. Sixty-eight (71.6%) patients presented a favourable clinical response. Microbiological eradication was documented in 42.1% (40/95) of the episodes. The global ICU mortality was 36.5%. Univariate analysis showed that 30-day mortality was significantly associated (P < 0.05) with Charlson Index at ICU admission and the need of life-supporting therapies.
    Conclusions: C/T appeared to be an effective therapy for severe infections due to P. aeruginosa in critically ill patients. Mortality was mainly related to the severity of the infection. No benefit was observed with high-dose C/T or combination therapy with other antibiotics.
    Mesh-Begriff(e) Adult ; Aged ; Aged, 80 and over ; Anti-Bacterial Agents/therapeutic use ; Cephalosporins/therapeutic use ; Critical Illness ; Cross Infection/drug therapy ; Cross Infection/mortality ; Dose-Response Relationship, Drug ; Drug Resistance, Multiple, Bacterial ; Female ; Humans ; Intensive Care Units ; Male ; Microbial Sensitivity Tests ; Middle Aged ; Pseudomonas Infections/drug therapy ; Pseudomonas Infections/mortality ; Pseudomonas aeruginosa/drug effects ; Pseudomonas aeruginosa/isolation & purification ; Retrospective Studies ; Spain ; Tazobactam/therapeutic use ; Treatment Outcome
    Chemische Substanzen Anti-Bacterial Agents ; Cephalosporins ; ceftolozane, tazobactam drug combination ; Tazobactam (SE10G96M8W)
    Sprache Englisch
    Erscheinungsdatum 2021-01-19
    Erscheinungsland Netherlands
    Dokumenttyp Journal Article ; Multicenter Study ; Observational Study
    ZDB-ID 1093977-5
    ISSN 1872-7913 ; 0924-8579
    ISSN (online) 1872-7913
    ISSN 0924-8579
    DOI 10.1016/j.ijantimicag.2020.106270
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 3368: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 500: Hefte anzeigen

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang